Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04638946 · ClinicalTrials.gov registry record · NA

Exercise for Anxiety

A NA study of Anxiety, sponsored by NYU Langone Health.

Active
Registry status
NA
Development phase
111
Enrollment target
1
Study location

NCT04638946: Active NA study of Anxiety, sponsored by NYU Langone Health.

NCT04638946 is a NA study of Anxiety that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 111 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04638946, a NA study of Anxiety, is active but no longer recruiting, sponsored by NYU Langone Health.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
111 participants
Enrollment target
1
Study location

Study Summary

90 sedentary adults with a primary anxiety disorder and high anxiety sensitivity will be randomized to either 8 weeks of 1) low intensity exercise, or 2) flexible titration to high intensity exercise (HIE). Blinded, validated clinician-rated and patient-rated outcomes will be assessed over treatment and at 1- and 3-month follow-up. To better understand what mechanisms influence decisions to exercise in the real-world, we will use of heart rate (HR) as an objective mechanistic target for exercise intensity, examine changes in valuation of exercise through a neuroeconomics task, examine changes in interoceptive sensitivity with a heartbeat detection task, and integrate of ecological momentary assessment (EMA) to measure effects of immediate changes in mood with exercise on anxiety outcomes and adherence.

Primary Outcome

The ASI-3 is an 18-item measure of fear of anxiety sensations with three subscales (physical, cognitive, social concerns). The total score ranges from 0 (lowest anxiety sensitivity) to 72 (highest anxiety sensitivity).

Conditions Studied

Interventions

  • BEHAVIORAL Titration to high intensity exercise (T-HIE)
  • BEHAVIORAL Low intensity exercise prescription

Study Locations (1)

New York

  • NYU Langone Health - New York

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2021-06-30
Est. Completion 2026-04-30
Phase NA
NYU Langone Health

1,164 total trials

What the registry record for NCT04638946 still lists

NCT04638946 is an interventional study that assigns participants to a tested intervention. The registered 111 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (75% lower).

The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Titration to high intensity exercise (T-HIE) is the first listed.

NCT04638946 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04638946 about?

NCT04638946 is a clinical study titled "Exercise for Anxiety". 90 sedentary adults with a primary anxiety disorder and high anxiety sensitivity will be randomized to either 8 weeks of 1) low intensity exercise, or 2) flexible titration to high intensity exercise (HIE). Blinded, validated clinician-rated and patient-rated outcomes will be assessed over treatment...

What is the current status of trial NCT04638946?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 111 participants. The study started on 2021-06-30. Estimated completion is 2026-04-30.

What conditions does trial NCT04638946 study?

This clinical trial studies the following conditions: Anxiety.

What interventions are being tested in trial NCT04638946?

The interventions under investigation include: Titration to high intensity exercise (T-HIE) (BEHAVIORAL), Low intensity exercise prescription (BEHAVIORAL).

Who is sponsoring clinical trial NCT04638946?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04638946 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04638946's enrollment target sits among peer trials

111 149th of 364 higher than 214 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03875716 · 111 participants · NA

    Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

  • NCT04693468 · 111 participants · Phase 1

    Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

  • NCT05263050 · 111 participants · Phase 2

    Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

  • NCT05600842 · 111 participants

    De-escalated Radiation for Human Papillomavirus-Positive Squamous Cell Carcinoma of the Oropharynx

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04638946, the US trial registry maintained by the National Library of Medicine. NCT04638946 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.